Obermatt
See Similar Stocks →

Soleno Therapeutics

NAQ:SLNO · US8342033094
BiotechnologySmall

360

67
Medium confidence — indicative
Profit price9
Owner Earnings Yield88
Dividend Yield1
Price/Sales89
EV / Gross Profit61
Price/Book55
Return on Capital91
Cash Return on Capital90
Return on Equity92
EBIT Margin78
Gross Profitability83
Accruals2
Owner Earnings Margin87
Sales growth100
Profit growth100
Reinvestment94
Price momentum16
Debt load33
Refinancing100
Debt Payback100
Liquidity100
Analyst ratings1
Expectations trend1
Market mood100
Value Creation20/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Soleno Therapeutics generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePrivate Company
ExchangeNASDAQGM
Founded1999
Employees178
Websitesoleno.life
ISINUS8342033094
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Health DiagnosticsDiabetesChronic DiseasesPain ManagementObesityNeurologyPsychiatryGeneticsCentral Nervous SystemNeuroscienceGenetic DisorderBiotechnologyMedicalPharmaceutical

Description

Soleno Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutics for the treatment of rare diseases. On March 26, 2025, the company announced that its lead product candidate, VYKAT XR (diazoxide choline) extended-release tablets,…

Analysis

Quality compounder

Soleno Therapeutics, Inc. is a quality compounder: a well-run business trading at a price that reflects what it is worth. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is expensive. You pay 27.7× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone.

The trajectory is mixed and the balance sheet is adequate. The company scores 20/20 on our value-creation score: strong value creator. Analyst sentiment is cautious.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
89
—
—
—
Price/Earnings
3
—
—
—
Price/Book
55
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
69
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Soleno Therapeutics with its peers
Jade Biosciences
NAQ:JBIO
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Sagimet Biosciences
NMQ:SGMT
59
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Protara Therapeutics
NMQ:TARA
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Larimar Therapeutics
NMQ:LRMR
26
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
MediciNova
NMQ:MNOV
21
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Pyxis Oncology
NSQ:PYXS
49
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →